Matches in Wikidata for { <http://www.wikidata.org/entity/Q62579839> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q62579839 description "artículu científicu" @default.
- Q62579839 description "im September 2016 veröffentlichter wissenschaftlicher Artikel" @default.
- Q62579839 description "wetenschappelijk artikel" @default.
- Q62579839 description "наукова стаття, опублікована у вересні 2016" @default.
- Q62579839 name "F23Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial" @default.
- Q62579839 name "F23Fulvestrant" @default.
- Q62579839 type Item @default.
- Q62579839 label "F23Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial" @default.
- Q62579839 label "F23Fulvestrant" @default.
- Q62579839 prefLabel "F23Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial" @default.
- Q62579839 prefLabel "F23Fulvestrant" @default.
- Q62579839 P1433 Q62579839-0E664877-D508-40B1-9262-AF977F05BA5F @default.
- Q62579839 P1476 Q62579839-FAB50AD5-4276-4A3C-BC36-74D081810FA0 @default.
- Q62579839 P2093 Q62579839-029482D3-A256-43BA-A4AD-52774541248D @default.
- Q62579839 P2093 Q62579839-0D7A7642-0241-4C60-8D01-D53394064CF5 @default.
- Q62579839 P2093 Q62579839-15DB99EA-2B33-4ED8-BC3A-7DB5FBF7B27A @default.
- Q62579839 P2093 Q62579839-1CC82869-8C70-4EE6-B38C-93FB86B29064 @default.
- Q62579839 P2093 Q62579839-63923327-ABBE-4CEC-AF9A-87AB30C56F77 @default.
- Q62579839 P2093 Q62579839-80BAA988-2112-4A09-84FE-877FA3D7C4B2 @default.
- Q62579839 P2093 Q62579839-A4B648FD-05B2-4258-810C-B20E56C4C19F @default.
- Q62579839 P2093 Q62579839-AC660B56-18CC-4A3C-8097-EE1A16A80277 @default.
- Q62579839 P2093 Q62579839-B96A2123-E116-423B-AF40-7283ABBE7CFC @default.
- Q62579839 P2093 Q62579839-E0830083-115C-4BC4-B2F8-2E07D77BB0C6 @default.
- Q62579839 P2093 Q62579839-E9385DD9-C9C0-4C06-ABF7-257842EEAB62 @default.
- Q62579839 P2093 Q62579839-EEA8006E-40F5-45DE-A944-E0C309CE1A00 @default.
- Q62579839 P2093 Q62579839-F749F3C4-4B54-479A-92A8-B2F56A00F699 @default.
- Q62579839 P304 Q62579839-CC721DD1-F7A3-4158-B9B7-FAE717C54B02 @default.
- Q62579839 P31 Q62579839-8FBFB264-F72C-43B7-94B7-CEA7EA3F5F49 @default.
- Q62579839 P356 Q62579839-BF090377-8700-4C00-9918-2F09A043D14D @default.
- Q62579839 P433 Q62579839-B00DF550-0C25-424A-964C-06B37A8B9F66 @default.
- Q62579839 P478 Q62579839-CB613AEC-3D5E-42EC-BEFE-5B10BD1F9050 @default.
- Q62579839 P50 Q62579839-C693AEA3-0911-45E2-80C2-B2A78E79555F @default.
- Q62579839 P577 Q62579839-DD1A68EF-09D3-4FE6-90EA-9E9336E6E80E @default.
- Q62579839 P356 MDW337.23 @default.
- Q62579839 P1433 Q326122 @default.
- Q62579839 P1476 "F23Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial" @default.
- Q62579839 P2093 "A. Vaccaro" @default.
- Q62579839 P2093 "C. Natoli" @default.
- Q62579839 P2093 "C.L. Roma" @default.
- Q62579839 P2093 "E. Iattoni" @default.
- Q62579839 P2093 "E.M. Ruggeri" @default.
- Q62579839 P2093 "G. D'Auria" @default.
- Q62579839 P2093 "L. Iezzi" @default.
- Q62579839 P2093 "L. Moscetti" @default.
- Q62579839 P2093 "L. Pizzuti" @default.
- Q62579839 P2093 "M. Mauri" @default.
- Q62579839 P2093 "M.A. Fabbri" @default.
- Q62579839 P2093 "P. Vici" @default.
- Q62579839 P2093 "T. Gamucci" @default.
- Q62579839 P304 "iv66-iv66" @default.
- Q62579839 P31 Q13442814 @default.
- Q62579839 P356 "10.1093/ANNONC/MDW337.23" @default.
- Q62579839 P433 "suppl_4" @default.
- Q62579839 P478 "27" @default.
- Q62579839 P50 Q37383620 @default.
- Q62579839 P577 "2016-09-01T00:00:00Z" @default.